Bio-Rad Laboratories, a worldwide leader in life science research and clinical diagnostic equipment, has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human-programmed death receptor-1, and are suitable for bioanalysis and drug monitoring.
Cemiplimab is a checkpoint inhibitor, which is blocking T cells'' interactions with the PD-1 antibody, as well as PD-L1 and PD-L2, and thus promoting T cells to be attacked by cancer cells. Three fully human IgG1 antibodies with varying affinity levels are ideal for site-directed conjugation or quick conversion to a bivalent Fab or an Ig-like format within an hour. ELISA is also available to use.
The recombinant antibodies are obtained using the Human Combinatorial Antibody Libraries (HuCAL) and CysDisplay, a proprietary technique of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant process results in batch-to-batch consistency, ensuring reproducible results and a secure supply throughout the assay lifecycle.
Bio-Rad''s long-term selection of recombinant, monoclonal, and anti-idiotypic antibodies continues to expand. These crucial antibody reagents help researchers in developing bioanalytical tests for checkpoint inhibitor drugs, according to Amanda Turner, a bio-Rad product manager. The addition of TrailBlazer Antibodies to the range allows for greater flexibility in bioanalytical assay design.
The anti-cemiplimab antibodies are approved for in vitro research purposes, and for commercial applications that are providing in vitro testing services to assist preclinical and clinical drugs and biosimilar development.
